KEY FEATURES 

Therapeutic Class: Dual incretin receptor agonist (GLP‑1 and GIP)

Primary Uses: Type 2 diabetes management, chronic weight management

Mechanism of Action :

Activates GLP‑1 receptors → enhances insulin secretion and reduces glucagon

Activates GIP receptors → improves insulin sensitivity and metabolic control

Combined dual‑pathway → superior glycemic and weight‑loss outcomes

Clinical benefits:

Significant HbA1c reduction (average −2.0%)

Up to 20% body weight loss in obesity trials

Cardiometabolic protection (ongoing studies show reduced cardiovascular risk)

TECHNICAL SPECIFICATIONS 

Parameter                  Description                                                                                                 -Molecular Type           Synthetic peptide    (tirzepatide)                                                            
-Molecular Formula      C₃₈₃H₅₈₉N₈₅O₁₁₅                                                                                              
-Molecular Weight           ≈ 4813.5 g/                                                                                            
-Dosage Forms             Prefilled injection pens (once‑weekly)                                                                       
-Strengths Available      2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg                                                                  
-Administration Route     Subcutaneous injection                                                                                       
-Storage Conditions     Refrigerate (2–8 °C); stable at room temperature ≤ 21 days                                                   
-Stability                        24 months shelf life under recommended conditions                                                            
-Regulatory Identifiers    NDA 215866 (Mounjaro®), NDA 217806 (Zepbound™)                                                               
-Manufacturer                Eli Lilly and Company                                                                                        
-Safety Profile                Common: nausea, diarrhea, decreased appetite; Serious: pancreatitis, gallbladder disease, rare thyroid tumors|
-Contraindications         Type 1 diabetes, pregnancy, breastfeeding, history of medullary thyroid carcinoma or MEN2      

AVAILABLE CONFIGURATIONS            

Brand/ Models: 

Mounjaro(Diabetes)

Zepbound(Weight management)

Delivery Format :

Prefilled  single use injection pens

Strenght Variants:

2.5-15mg

Packaging:

Individual retail boxes or bulk cartons

Labeling:

Brand, strength, NDC code

Compliance:

FDA-approved finished drug products